

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

1-35. (Canceled)

36-42. (Canceled)

~~1~~ ~~42.~~ (Previously Presented) A method of inhibiting the cellular effects of VEGF in a mammal comprising administering to the mammal an effective amount of truncated Flk-1 receptor protein, lacking a functional Flk-1 cytoplasmic domain, which inhibits the cellular effects of VEGF binding.

44-46. (Canceled)

47-48. (Canceled)

~~2~~ ~~49.~~ (Previously Presented) The method of claim ~~43~~<sup>1</sup>, wherein said truncated Flk-1 receptor protein has a functional Flk-1 extracellular and transmembrane domain.

~~3~~ ~~50.~~ (Previously Presented) The method of claim ~~49~~<sup>2</sup>, wherein said truncated Flk-1 receptor protein comprises a nucleotide sequence encoding amino acids 1 through 806 of Flk-1.

~~4~~ ~~51.~~ (Previously Presented) The method of claim ~~49~~<sup>2</sup>, wherein said truncated Flk-1 receptor protein comprises a nucleotide sequence encoding amino acids 1 through 806 of Flk-1 but lacking the 561 COOH-terminal amino acids of the intracellular kinase domain of Flk-1.